TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches

TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represent a biologically and clinically distinct subset of myeloid malignancies characterized by poor prognosis, resistance to standard therapies, and high rates of relapse. TP53 mutations, particularly biallelic are frequ...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shweta Deshpande, Wing Fai Li, Junmin Song, Mark Forsberg, Claudio Cerchione, Giovanni Martinelli, Marina Konopleva
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-02-01
Edice:	Frontiers in Oncology
Témata:	acute myeloid leukemia myelodysplastic syndromes TP53 mutation p53 hypomethylating agents venetoclax
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1735418/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!